P Thor Straten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4660732/publications.pdf Version: 2024-02-01



D THOD STDATEN

#	Article	IF	CITATIONS
1	Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metabolism, 2016, 23, 554-562.	16.2	572
2	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nature Biotechnology, 2016, 34, 1037-1045.	17.5	279
3	Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenvironment, 2013, 6, 123-133.	3.1	263
4	Collagen density regulates the activity of tumor-infiltrating T cells. , 2019, 7, 68.		239
5	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research, 2016, 22, 3734-3745.	7.0	234
6	Immune-suppressive properties of the tumor microenvironment. Cancer Immunology, Immunotherapy, 2013, 62, 1137-1148.	4.2	179
7	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunology, Immunotherapy, 2014, 63, 1177-1187.	4.2	135
8	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 2012, 10, 169.	4.4	134
9	Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nature Protocols, 2012, 7, 891-902.	12.0	131
10	More tricks with tetramers: a practical guide to staining T cells with peptide– <scp>MHC</scp> multimers. Immunology, 2015, 146, 11-22.	4.4	106
11	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Research, 2015, 75, 3747-3759.	0.9	93
12	Exercise and cancer: from "healthy―to "therapeutic�. Cancer Immunology, Immunotherapy, 2017, 66, 667-671.	4.2	92
13	Peptide–MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. Journal of Immunology, 2018, 200, 2263-2279.	0.8	87
14	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. Clinical Cancer Research, 2014, 20, 1768-1778.	7.0	81
15	The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 2018, 32, 429-437.	7.2	76
16	Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 2091-2103.	4.2	69
17	Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-1±. Blood, 2011, 118, 2170-2173.	1.4	59
18	Antibody Stabilization of Peptide–MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. Journal of Immunology, 2015, 194, 463-474.	0.8	55

P THOR STRATEN

#	Article	IF	CITATIONS
19	The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia, 2017, 31, 495-498.	7.2	51
20	Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. OncoImmunology, 2018, 7, e1450715.	4.6	48
21	Expansion of circulating CD56 ^{bright} natural killer cells in patients with JAK2â€positive chronic myeloproliferative neoplasms during treatment with interferonâ€î±. European Journal of Haematology, 2015, 94, 227-234.	2.2	45
22	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
23	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
24	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNI ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
25	MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells. Cancer Immunology Research, 2019, 7, 1472-1484.	3.4	39
26	Spontaneous Immunity against Bcl-xL in Cancer Patients. Journal of Immunology, 2005, 175, 2709-2714.	0.8	38
27	TAM Receptor Inhibition–Implications for Cancer and the Immune System. Cancers, 2021, 13, 1195.	3.7	37
28	Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. , 1997, 70, 582-586.		30
29	Interferonâ€Î± induces marked alterations in circulating regulatory T cells, <scp>NK</scp> cell subsets, and dendritic cells in patients with <scp>JAK</scp> 2V617Fâ€positive essential thrombocythemia and polycythemia vera. European Journal of Haematology, 2016, 97, 83-92.	2.2	30
30	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncolmmunology, 2016, 5, e1207842.	4.6	29
31	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
32	Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncolmmunology, 2018, 7, e1412029.	4.6	27
33	Targetless T cells in cancer immunotherapy. , 2016, 4, 23.		26
34	TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting. Cancer Immunology, Immunotherapy, 2020, 69, 237-244.	4.2	26
35	Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. Cells, 2018, 7, 108.	4.1	23
36	Design and validation of conditional ligands for <scp>HLAâ€B</scp> *08:01, <scp>HLAâ€B</scp> *15:01, <scp>HLAâ€B</scp> *35:01, and <scp>HLAâ€B</scp> *44:05. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 967-975.	1.5	21

P THOR STRATEN

#	Article	IF	CITATIONS
37	The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget, 2010, 1, 239-45.	1.8	21
38	Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens. Frontiers in Immunology, 2021, 12, 645131.	4.8	19
39	Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity. Journal of Allergy and Clinical Immunology, 2018, 142, 1983-1987.	2.9	17
40	Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investigation, 2016, 3, 95-95.	3.0	16
41	Expansion With IL-15 Increases Cytotoxicity of Vγ9Vβ T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet. Frontiers in Immunology, 2020, 11, 1868.	4.8	14
42	Inflammation induced PD-L1-specific T cells. Cell Stress, 2019, 3, 319-327.	3.2	13
43	Self-reactive T cells: suppressing the suppressors. Cancer Immunology, Immunotherapy, 2014, 63, 313-319.	4.2	11
44	Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. Methods in Molecular Biology, 2016, 1428, 261-276.	0.9	11
45	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. PLoS ONE, 2015, 10, e0131934.	2.5	11
46	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI) Tj ETQq0	0 0 rgBT / 2.6	Overlock 10 1
47	T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. Oncolmmunology, 2019, 8, e1663107.	4.6	9
48	Adoptive Cell Transfer in the Treatment of Metastatic Melanoma. Journal of Investigative Dermatology, 2009, 129, 2743-2745.	0.7	8
49	Modeling Metastatic Colonization in a Decellularized Organ Scaffoldâ€Based Perfusion Bioreactor. Advanced Healthcare Materials, 2022, 11, e2100684.	7.6	7
50	The capacity of CD4+ Vγ9VΠ2 T cells to kill cancer cells correlates with co-expression of CD56. Cytotherapy, 2021, 23, 582-589.	0.7	6
51	(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. PLoS ONE, 2016, 11, e0168210.	2.5	5
52	Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncolmmunology, 2014, 3, e953411.	4.6	4
53	The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2016, 136, 866-869.	0.7	4
54	Exercise: A new role for an old tool. Molecular and Cellular Oncology, 2016, 3, e1163005.	0.7	4

P THOR STRATEN

#	Article	IF	CITATIONS
55	Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. Journal of Investigative Dermatology, 2022, 142, 239-243.e13.	0.7	3
56	Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome. Oncotarget, 2019, 10, 4894-4906.	1.8	3
57	Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells, 2012, 1, 51-60.	4.1	2
58	Adoptive T-cell therapy (ACT) with TILs for metastatic melanoma: Clinical responses and durable persistence of anticancer responses in peripheral blood Journal of Clinical Oncology, 2013, 31, 3028-3028.	1.6	2
59	Exercise suppresses tumor growth through epinephrine- and IL-6-dependent mobilization and redistribution of NK cells. , 2015, 3, P246.		1
60	Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres' organisation. Ecancermedicalscience, 2016, 10, 691.	1.1	1
61	Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. , 1997, 70, 582.		1
62	Real-time Monitoring of Mitochondrial Respiration in Cytokine-differentiated Human Primary T Cells. Journal of Visualized Experiments, 2021, , .	0.3	1
63	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	4.8	0